Citigroup’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-20,000
| Closed | -$2.62M | – | 5579 |
|
|
2024
Q4 | $2.62M | Sell |
20,000
-17,400
| -47% | -$2.44M | ﹤0.01% | 2584 |
|
|
2024
Q3 | $5.83M | Buy |
37,400
+17,400
| +87% | +$2.81M | ﹤0.01% | 1726 |
|
|
2024
Q2 | $3.12M | Hold |
20,000
| – | – | ﹤0.01% | 1990 |
|
|
2024
Q1 | $2.71M | Buy |
+20,000
| New | +$2.65M | ﹤0.01% | 2182 |
|
|
2023
Q4 | – | Sell |
-62,450
| Closed | -$8.46M | – | 5699 |
|
|
2023
Q3 | $8.46M | Buy |
+62,450
| New | +$8.53M | 0.01% | 1177 |
|
|
2022
Q1 | – | Sell |
-26,940
| Closed | -$3.14M | – | 6301 |
|
|
2021
Q4 | $3.14M | Sell |
26,940
-60,000
| -69% | -$7.06M | ﹤0.01% | 2227 |
|
|
2021
Q3 | $10.4M | Buy |
86,940
+85,440
| +5,696% | +$9.95M | 0.01% | 1380 |
|
|
2021
Q2 | $180K | Hold |
1,500
| – | – | ﹤0.01% | 4284 |
|
|
2021
Q1 | $149K | Sell |
1,500
-53,850
| -97% | -$5.41M | ﹤0.01% | 4176 |
|
|
2020
Q4 | $5.53M | Sell |
55,350
-14,550
| -21% | -$1.54M | ﹤0.01% | 2002 |
|
|
2020
Q3 | $7.66M | Sell |
69,900
-17,800
| -20% | -$1.98M | 0.01% | 1575 |
|
|
2020
Q2 | $9.28M | Buy |
87,700
+16,800
| +24% | +$1.74M | 0.01% | 1356 |
|
|
2020
Q1 | $6.33M | Buy |
70,900
+13,200
| +23% | +$1.24M | 0.01% | 1485 |
|
|
2019
Q4 | $5.75M | Sell |
57,700
-11,850
| -17% | -$1.12M | ﹤0.01% | 1922 |
|
|
2019
Q3 | $6.2M | Buy |
69,550
+13,450
| +24% | +$1.17M | ﹤0.01% | 1750 |
|
|
2019
Q2 | $4.63M | Buy |
56,100
+4,550
| +9% | +$357K | ﹤0.01% | 2037 |
|
|
2019
Q1 | $4.17M | Sell |
51,550
-59,550
| -54% | -$4.69M | ﹤0.01% | 1953 |
|
|
2018
Q4 | $8.44M | Buy |
111,100
+35,250
| +46% | +$2.75M | 0.01% | 1384 |
|
|
2018
Q3 | $6M | Sell |
75,850
-50,900
| -40% | -$3.85M | 0.01% | 1681 |
|
|
2018
Q2 | $8.9M | Sell |
126,750
-31,700
| -20% | -$2.28M | 0.01% | 1375 |
|
|
2018
Q1 | $11.1M | Sell |
158,450
-68,250
| -30% | -$4.73M | 0.01% | 1164 |
|
|
2017
Q4 | $15.7M | Buy |
226,700
+15,300
| +7% | +$1.03M | 0.01% | 985 |
|
|
2017
Q3 | $14.3M | Sell |
211,400
-138,800
| -40% | -$8.77M | 0.01% | 990 |
|
|
2017
Q2 | $23.9M | Buy |
350,200
+210,300
| +150% | +$13.7M | 0.02% | 672 |
|
|
2017
Q1 | $8.71M | Buy |
139,900
+45,000
| +47% | +$2.62M | 0.01% | 1244 |
|
|
2016
Q4 | $5.18M | Buy |
94,900
+8,700
| +10% | +$494K | ﹤0.01% | 1800 |
|
|
2016
Q3 | $5.67M | Sell |
86,200
-63,850
| -43% | -$4.17M | 0.01% | 1552 |
|
|
2016
Q2 | $9.06M | Buy |
150,050
+86,100
| +135% | +$5M | 0.01% | 1100 |
|
|
2016
Q1 | $3.6M | Sell |
63,950
-27,700
| -30% | -$1.66M | ﹤0.01% | 1861 |
|
|
2015
Q4 | $6.22M | Buy |
91,650
+10,850
| +13% | +$711K | 0.01% | 1504 |
|
|
2015
Q3 | $5.14M | Sell |
80,800
-12,100
| -13% | -$796K | ﹤0.01% | 1637 |
|
|
2015
Q2 | $5.92M | Sell |
92,900
-66,600
| -42% | -$4.56M | 0.01% | 1596 |
|
|
2015
Q1 | $10.9M | Sell |
159,500
-271,800
| -63% | -$18.9M | 0.01% | 1127 |
|
|
2014
Q4 | $30.4M | Sell |
431,300
-81,500
| -16% | -$5.84M | 0.03% | 600 |
|
|
2014
Q3 | $36.6M | Buy |
512,800
+320,000
| +166% | +$23.4M | 0.03% | 517 |
|
|
2014
Q2 | $14.3M | Buy |
192,800
+55,500
| +40% | +$4.01M | 0.01% | 1002 |
|
|
2014
Q1 | $8.91M | Sell |
137,300
-108,700
| -44% | -$7.02M | 0.01% | 1238 |
|
|
2013
Q4 | $14.6M | Buy |
246,000
+15,100
| +7% | +$820K | 0.01% | 954 |
|
|
2013
Q3 | $12M | Buy |
230,900
+27,600
| +14% | +$1.39M | 0.01% | 1034 |
|
|
2013
Q2 | $9.62M | Buy |
+203,300
| New | +$10.4M | 0.01% | 1112 |
|
Other funds holding AZN
IA
VCM
VAM
Citigroup's AZN Position: Q1 2026 in Review
Citigroup increased its AstraZeneca (AZN) stake by 20% in Q1 2026, buying an estimated $121M and bringing the position to 3,705,472 shares worth $718M. The position accounts for 0.31% of the portfolio, ranked #60.
Citigroup first reported a position in AZN in Q2 2013 and has held it in 52 quarters since. The position peaked at $720M in Q2 2021. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Citigroup held 3,705,472 shares of AstraZeneca worth $718M as of Q1 2026.
- Citigroup bought 628,092 AstraZeneca shares in Q1 2026, an estimated $121M.
- AstraZeneca made up 0.31% of Citigroup's portfolio in Q1 2026, its #60 holding.
- Citigroup first reported a position in AstraZeneca in Q2 2013 and has held it in 52 quarters since.
- Citigroup's AstraZeneca position peaked at $720M in Q2 2021.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.